Drugs / TU-100
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04742907 | Jul 2021 → Mar 2024 | — | Tsumura USA | Completed | Missed primary |
| Phase 2 | NCT02074579 | Jul 2014 → Apr 2016 | irritable bowel syndrome | Tsumura USA | Completed | No outcome recorded |
| Phase 2 | NCT01388933 | Sep 2011 → Sep 2013 | Crohn disease | Tsumura USA | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TU-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04742907 ↗ |
| Known as | Daikenchuto | “A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease” NCT01388933 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Tsumura's TU-100 is a modern herbal product” NCT01388933 ↗ |
| Route | Oral | “15g daily, orally as 5g three times daily for 8 consecutive weeks” NCT01388933 ↗ |